Frigjør midler for å kjøpe mer Funcom? Eller for å være med på rettet emisjon
1 Like
Jeg har mye funcom, før var jeg litt mer omtrent all-in (alt er relativt), men nå er jeg litt mer forsiktig. Kanskje synd, det er i funcom og star med blytung eksponering jeg har tjent 90% av pengene mine. Ser ut som om jeg kom for tidlig inn i PCIB.
2 Likes
Der var det en som hadde dårlig tid med å komme seg ut av aksjen.
17.10.2016 10:45:27: PCI Biotech: Results from the bile duct cancer study will be presented as late-breaking news at United European Gastroenterology Week
Oslo, October 17, 2016 - PCI Biotech today announced that an abstract with results from the phase I bile duct cancer study has been selected for oral presentation as late-breaking news at the United European Gastroenterology (UEG) Week.
The results will be presented by Dr. Alexander Dechêne, University Hospital Essen, Germany, who is one of the investigators in the phase I study. The presentation “Phase I study with photochemical Internalisation (PCI) - a novel technology for treatment of perihilar cholangiocarcinoma” will be held today at 15:00 local time in room M at the Austria Center Vienna (ACV), Vienna, Austria. The presentation will be made available on PCI Biotech’s home page.
About United European Gastroenterology (UEG)
United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive health. The member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, GI oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaChem programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For more information visit: www.pcibiotech.com
Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
2 Likes
Hehe. Man husker jo hva som skjedde når Nano begynte å snakke om late breaking…
1 Like
Ja jeg husker det, men PCIB har ikke fått samme kursutvikling, kanskje pga. at markedet frykter dumpings-emisjon. Jeg tror ikke at det blir dumpingsemisjon når fase 1 resultatene ble så gode som de ble. Jeg synes fremdeles kursen ikke viser på noen som helst måte at selskapet faktisk har lykkes i fase 1.
1 Like
Det er sånt som også kan bli en typisk sell the news event.
2 Likes
A total of 16 patients were treated in the dose escalating Phase I part of this study. Four different dose cohorts were tested. The last patient completed the 6 months follow-up period in September 2016. Of the 16 patients treated, 11 completed the 8 cycles of combination therapy, and 5 patients were early withdrawals. No patients expired while still on study. The treatment was well tolerated with no DLTs, and no serious safety concerns were raised. In the last two dose cohorts, independent radiological evaluation showed that 7 out of 8 patients had evaluable tumor, and four of these showed an objective tumor response at six months, including two complete responses.
Conclusion
The patient number in this clinical study is small, but the results indicate high durable objective tumor response rates. The early signs of efficacy using PCI treatment with fimaporfin and gemcitabine are encouraging.
Late-breaking abstracts are abstracts which describe important current research advances and which have not been submitted previously.
Only state-of-the-art research with up-to-date results is considered. Authors of standard abstracts are not prohibited from submitting late-breaking abstracts. Work presented at another conference this year will be considered if the abstract includes innovative scientific findings achieved in the meantime. The selection will be based on scientific quality and novelty of research either in basic or clinical science. Please note that late-breaking abstracts are not a second chance for those who missed the official abstract deadline."
2 Likes
her er link til presentasjonen:
http://www.netfonds.no/quotes/release.php?id=20161017.GlobeNewswire.HUG2049371
1 Like
Oslo, October 17, 2016 - reference is made to the announced oral presentation from the phase I bile duct cancer study as late-breaking news at the United European Gastroenterology (UEG) Week. The presentation “Phase I study with photochemical Internalisation (PCI) - a novel technology for treatment of perihilar cholangiocarcinoma” by Dr. Alexander Dechêne, University Hospital Essen, Germany, is attached.
About United European Gastroenterology (UEG)
United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive health. The member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, GI oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaChem programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For more information visit: www.pcibiotech.com
Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Ph I CCA presentation UEGW Oct 2016
Opp 35% i dag. Kan endelig vendepunktet ha kommet for PCIB eller skal man rett ned igjen?
1 Like
Den som visste det. 
Men et imponerende hopp.
1 Like
Grattis med denne Alex! Håper ikke du solgte fortidlig.
Er fremdeles godt med men reduserte litt, mest fordi markedet var totalt uenig med meg i en lang periode. Om dagens oppgang holder seg eller ikke.har jeg ikke peiling på. Det var svært lite nytt i den presentasjonen og det trekker ned.på den andre siden er dette etter mitt syn den mest undervurderte aksjen i norsk biotech og en eller gang oppdager vel markedet potensialet.
1 Like
TRor det blir videre opptur idag, ser flere flytter penger fra Nano ti PCIB.
Bra plukket, hadde den på radaren selv men trodde det skulle gå noe tid før det smalt 
1 Like
Aksjemarkedet er et rart sted. Så det var altså denne presentasjonen som egentlig inneholdt svært lite nytt ift det jeg visste fra før som skulle reprise PCIB. Hovedgrunnen til nedgangen i det siste er nok at kassa begynner å bli tom og det problemet er ikke løst. Litt skeptisk til om oppgangen holder. Men mcap på PCIB er fortsatt latterlig lav og en eller annen gang kommer reprisinga. Snøffelen på hegnar opererer med kursmål 90kr , andre 1000 kr. Slike kursmål skal man ta med en solid klype salt, men potensialet for noe virkelig stort er der.
3 Likes
Bare vente til emmisjonen er unnagjort mao.
1 Like
Hvis det kommer en emisjon da, partner kan komme tidlig. Uvanlig ja, men det skjer.
Som sagt på en annen tråd er det aksjer jeg er interessert i, kjøper jeg meg inn umiddelbart med minimum en mindre post… Selv om jeg håper på billigere inngang. Det er så irriterende å se et case som jeg vurderer stikke av pga. jeg var for treg eller for grådig.
Tror ikke Partner så tidlig når jeg ser hvor få pasienter det er.
Skal jeg vekte muligheten for Partner - Emmisjon.
Vil jeg tippe 10%-90%.
2 Likes
Hvis denne interessen holder seg burde en emisjon med lite rabatt være mulig. Det vil fjerne en usikkerhetsfaktor som har tynget aksjen en stund.
1 Like